Cabometyx (cabozantinib) is a brand-name oral tablet prescribed for certain types of cancer in adults and some children. The cost of the drug, with and without insurance, can depend on several ...

The previous Paralympic logo incorporated the Tae-Geuk, which is a traditional Korean decorative motif. According to oriental philosophy, Tae-Geuk refers to the ultimate reality from which all things ...

Leerink Partners analyst Andrew Berens has maintained their neutral stance on EXEL stock, giving a Hold rating today. Andrew Berens has given ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

The European Commission has approved Ipsen’s Cabometyx for liver cancer, in adults previously treated with Bayer’s Nexavar. The commission granted a marketing authorisation for Cabometyx ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

Exelixis’ cancer drug Cabometyx has been approved in a new liver cancer use in the US, providing a second line therapy option for patients previously treated with Bayer’s Nexavar.

Exelixis is pursuing an additional approval for Cabometyx in neuroendocrine tumors. The U.S. FDA has assigned an action date ...

Update 1:25pm: Adds Jefferies analyst comment. Exelixis (NASDAQ:EXEL) rose 5% as the patent trial over its Cabometyx drug ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil A ...

Exelixis (NASDAQ:EXEL) has released additional phase 3 data on Cabometyx (cabozantinib) in individuals with pancreatic neuroendocrine tumors (pNET) and with advanced extra-pancreatic ...

The company has a new logo, designed by Pentagram, that looks incredibly plain — especially compared to previous iterations of the logo that featured a rakish slant, two shades of blue ...